Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.

Authors
  • O'Donnell, John1
  • Preston, Richard A2
  • Mamikonyan, Grigor3
  • Stone, Emily4
  • Isaacs, Robin5
  • 1 Entasis Therapeutics, Waltham, Massachusetts, USA.
  • 2 Division of Clinical Pharmacology Phase I Unit, Miller School of Medicine University of Miami, Miami, Florida, USA.
  • 3 Clinartis LLC, Hollywood, Florida, USA.
  • 4 Spero Therapeutics, Cambridge, Massachusetts, USA.
  • 5 Entasis Therapeutics, Waltham, Massachusetts, USA [email protected]
Type
Published Article
Journal
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Publication Date
Sep 01, 2019
Volume
63
Issue
9
Identifiers
DOI: 10.1128/AAC.00794-19
PMID: 31307978
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Sulbactam-durlobactam is being developed for the treatment of infections caused by Acinetobacter baumannii, including those caused by multidrug- and carbapenem-resistant isolates. This was a phase 1 study to evaluate the effects of various degrees of renal impairment, including subjects with end-stage renal disease (ESRD) on hemodialysis (HD), on the pharmacokinetics and safety profile of durlobactam (also known as ETX2514) and sulbactam after single intravenous (i.v.) dose administration. For healthy subjects and those with mild or moderate renal impairment (RI), single 1,000-mg doses each of durlobactam and sulbactam via a 3-h i.v. infusion were administered, and for severe renal impairment, 500-mg doses were administered. For subjects with ESRD and HD, 500-mg i.v. doses each of durlobactam and sulbactam were administered post-HD and pre-HD, with a 1-week washout between doses. Among 34 subjects, decreasing renal function increased systemic exposure (peak plasma concentration [C max] and area under the concentration-time curve [AUC]) to durlobactam and sulbactam in a generally linear manner. In healthy subjects and in those with mild or moderate renal impairment, the majority of durlobactam and sulbactam was excreted in the urine, while approximately 40% or less was excreted in urine in subjects with severe renal impairment or ESRD. In subjects with ESRD, hemodialysis was effective at removing both durlobactam and sulbactam from plasma. Renal impairment had no effect of the safety/tolerability profile of durlobactam and sulbactam. In summary, RI and ESRD had a predictable effect on the pharmacokinetic (PK) profile of durlobactam and sulbactam with no adverse effects on the safety/tolerability profile. Durlobactam and sulbactam are cleared to a similar extent by renal elimination and are impacted similarly by renal impairment. The results from this study have been used with population PK modeling and nonclinically derived PK/PD (pharmacodynamic) exposure targets to establish dosage recommendations for durlobactam and sulbactam in patients with various degrees of RI. The dosing regimen of durlobactam-sulbactam will require adjustment in patients with severe renal insufficiency and in those with ESRD. Copyright © 2019 O’Donnell et al.

Report this publication

Statistics

Seen <100 times